For the quarter ending 2025-09-30, PALI had -$190K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,868 | -5,014 |
| Depreciation | 1 | 2 |
| Non-cash operating lease expense | 22 | 62 |
| Recurring fair value measurements of liabilities | -332 | 9 |
| Issuance of common stock to vendors | 0 | 0 |
| Write-off of deferred equity issuance costs | 0 | 75 |
| Loss on disposal of property and equipment | 0 | 0 |
| Stock-based compensation and related charges | 90 | 138 |
| Other | 61 | - |
| Prepaid and other current assets and other noncurrent assets | 519 | 18 |
| Accounts payable and accrued liabilities | -955 | 1,210 |
| Accrued compensation and benefits | 429 | -530 |
| Operating lease liabilities | -24 | -66 |
| Net cash used in operating activities | -3,553 | -4,150 |
| Payments on insurance financing debt | 100 | 80 |
| Proceeds from issuance of common stock and warrants | 0 | 0 |
| Proceeds from the exercise of warrants | 3,908 | 1 |
| Payment of warrant inducement issuance costs | 445 | 0 |
| Payment of equity issuance costs | 0 | 178 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 3 |
| Shares withheld for payment of employee withholding tax liability | 0 | 0 |
| Net cash provided by financing activities | 3,363 | -254 |
| Net decrease in cash, cash equivalents and restricted cash | -190 | -4,404 |
| Cash and cash equivalents at beginning of period | 9,847 | - |
| Cash and cash equivalents at end of period | 5,253 | - |
PALISADE BIO, INC. (PALI)
PALISADE BIO, INC. (PALI)